Biotechnology
Origin Agritech Expands GMO Trait Portfolio
BEIJING, July 12, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that it has entered into an exclusive rights agreement with Biology Research Institute of Chinese Academy of Agricultural Sciences for its dro...
2021-07-12 22:13
19472
Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US
SUZHOU, China, July 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase...
2021-07-11 21:03
20138
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
* ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile * ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South Ko...
2021-07-09 21:00
3421
Sequanta and Mission Bio announce strategic partnership
SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...
2021-07-09 15:44
2121
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...
2021-07-08 12:01
2473
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...
2021-07-06 21:06
18345
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...
2021-07-06 18:00
17467
Korea National Institute of Health (KNIH) conducts field inspection of companies with mRNA technology
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- Korea National Institute of
Health (KNIH), Korea's top research center in the field of hygiene and medicine
(with Mr. Kwon Jun-Wook as President) conducted a field inspection of key
companies with mRNA technology.
2021-07-01 21:00
2275
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
NEW YORK, June 29, 2021 /PRNewswire/ -- OnCusp Therapeutics (or "OnCusp"), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both inNew York and Shanghai. OnCusp succ...
2021-06-30 09:29
1710
Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"
SEOUL, South Korea, June 29, 2021 /PRNewswire/ -- Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the resul...
2021-06-29 21:00
2670
I-Mab Announces Upcoming Participation at July Conference
SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July. D...
2021-06-29 20:00
8567
First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON
* Novel and one-time intravitreal injection of ND4 gene therapy for the treatment of LHON potentially restored vision * Phase I/II/III clinical trial expected to enroll patients with LHON due to ND4 mutation WUHAN, China and SAN DIEGO, June 28, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd...
2021-06-28 21:33
1984
International experts join Microba Life Sciences inaugural IBD Advisory Panel
BRISBANE, Australia, June 28, 2021 /PRNewswire/ -- Precision microbiome science
company,Microba Life Sciences
2021-06-28 21:00
1902
ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury
DAEJEON, South Korea, June 28, 2021 /PRNewswire/ -- Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration withYonsei University of Seoul, South Korea. ...
2021-06-28 20:00
1760
InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL
BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the trea...
2021-06-28 16:02
10780
Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery
SHANGHAI, June 26, 2021 /PRNewswire/ -- Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and ...
2021-06-26 23:00
3961
World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years
* Independent modelling estimates the PromarkerD predictive test for diabetic kidney disease (DKD) would increase the quality of care and could save US payers almostUSD400 billion over 10 years * The US is home to 31 million adults with diabetes who are at risk of DKD - cost savings stem from...
2021-06-25 23:30
2968
Vazyme Brings COVID-19 Testing Solutions at Medlab 2021
DUBAI, UAE, June 25, 2021 /PRNewswire/ -- Chinese biotechnology company Nanjing Vazyme Biotech Co., Ltd (Vazyme) showcased its lineup of COVID-19 testing solutions and its point-of-care testing (POCT) in vitro diagnostic instruments at the 2021 Medlab Middle East, an industry-leading medical labo...
2021-06-25 15:31
1731
Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer
SHANGHAI, June 25, 2021 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong ...
2021-06-25 15:06
1710
Samsung Biologics Issues Its First Annual Sustainability Report
* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...
2021-06-25 09:01
22917
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 310 media titles]
2025-12-04 16:00
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
Hyundai Motor Group Fosters Collaboration with Hydrogen Industry Leaders at Hydrogen Council Global CEO Summit
[Picked up by 295 media titles]
2025-12-04 15:00
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
3550
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3061
